A Glucuronic Acid-Palmitoylethanolamide Conjugate (GLUPEA) Is an Innovative Drug Delivery System and a Potential Bioregulator
Laboratory studyOther animalsWith GLUPEA (a glucuronic acid-PEA conjugate prodrug, tested against ultramicronised PEA)
This study tested palmitoylethanolamide together with GLUPEA (a glucuronic acid-PEA conjugate prodrug, tested against ultramicronised PEA). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Cultured cells and stimulated keratinocytes; mice with colitis induced by dinitrobenzene sulfonic acid
- Dose used in the study
- GLUPEA at the same concentration as PEA in cells, and at the same dose as ultramicronised PEA in mice; amounts and route not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Cellular PEA and 2-AG levels; TRPV1 desensitisation to capsaicin; MCP-2 release from keratinocytes; colitis severity in mice.
What the authors reported
GLUPEA raised cellular PEA and 2-AG more than the same concentration of PEA and increased 2-AG-induced TRPV1 desensitisation. It inhibited MCP-2 release from stimulated keratinocytes and was almost as effective as ultramicronised PEA at reducing colitis in mice at the same dose.
Limits of this study
A cell and mouse study of a new prodrug; it cannot show effect in people. Three authors are employees of Epitech Group, and two are co-inventors on PEA or adelmidrol patents.
Source
PubMed 33672574 · doi:10.3390/cells10020450
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.